Caoyun Ju
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Caoyun Ju has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Can Zhang
State Key Laboratory of Natural Medicines, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 211198, China
23 shared publications Lingjing Xue
State Key Laboratory of Natural Medicines, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 211198, China
12 shared publicationsChunli Tian
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, PR China
4 shared publicationsJingwei Xue
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, PR China
4 shared publicationsMeixi Hao
State Key Laboratory of Natural Medicines, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 211198, China
4 shared publicationsYijun Chen
State Key Laboratory of Natural Medicines, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 211198, China
4 shared publications
Latest Publications
- 18 June 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (25) , 34952-34967
Microenvironment-Adaptive Dynamic Hydrogel with Hierarchical Therapeutic Functions for Infected Chronic Wound Healing
Infected chronic wounds are trapped in a vicious cycle of bacterial infection, oxidative stress, and inflammation. This dynamic and multifactorial pathology presents a formidable challenge that conventional dressings cannot adequately address. Herein, we report a microenvironment-adaptive dynamic hydrogel (BBR/CAT@Gel) engineered with hierarchical therapeutic functions to break this cascade. These functions consist of three integrated levels: contact killing, on-demand responsive release of antibacterial/antioxidant agents, and pro-regenerative microenvironment remodeling. To achieve these functions, the hydrogel is formed via dual dynamic covalent cross-linking through Schiff base and phenylboronate ester bonds between phenylboronic acid-grafted polylysine and chlorogenic acid-grafted oxidized hyaluronic acid, followed by encapsulation of berberine (BBR) and catalase (CAT). This reversible network endows the system with injectability, self-healing capacity, and tissue adhesion, enabling on-demand drug release in response to the acidic pH and reactive oxygen species (ROS) of the infected wound microenvironment. The hydrogel exerts multifaceted antibacterial effects through membrane disruption mediated by ε-polylysine and chlorogenic acid (CGA), as well as inhibition of bacterial protein synthesis induced by BBR. Concurrently, the released CAT and BBR provide ROS scavenging, while CGA contributes antioxidant activities, collectively alleviating oxidative stress, inhibiting macrophage M1 polarization, promoting cell migration, and facilitating angiogenesis. This hierarchical design achieves rapid bactericidal action alongside sustained microenvironment remodeling. Based on these merits, BBR/CAT@Gel rapidly cleared infection and achieved complete epidermal regeneration with well-organized collagen deposition in a mouse model of infected chronic wounds. This work establishes a rationally designed, microenvironment-adaptive hydrogel platform that integrates hierarchical therapeutic mechanisms, offering a compelling strategy for advanced chronic wound management.
- 18 June 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (25) , 34952-34967
Microenvironment-Adaptive Dynamic Hydrogel with Hierarchical Therapeutic Functions for Infected Chronic Wound Healing
Infected chronic wounds are trapped in a vicious cycle of bacterial infection, oxidative stress, and inflammation. This dynamic and multifactorial pathology presents a formidable challenge that conventional dressings cannot adequately address. Herein, we report a microenvironment-adaptive dynamic hydrogel (BBR/CAT@Gel) engineered with hierarchical therapeutic functions to break this cascade. These functions consist of three integrated levels: contact killing, on-demand responsive release of antibacterial/antioxidant agents, and pro-regenerative microenvironment remodeling. To achieve these functions, the hydrogel is formed via dual dynamic covalent cross-linking through Schiff base and phenylboronate ester bonds between phenylboronic acid-grafted polylysine and chlorogenic acid-grafted oxidized hyaluronic acid, followed by encapsulation of berberine (BBR) and catalase (CAT). This reversible network endows the system with injectability, self-healing capacity, and tissue adhesion, enabling on-demand drug release in response to the acidic pH and reactive oxygen species (ROS) of the infected wound microenvironment. The hydrogel exerts multifaceted antibacterial effects through membrane disruption mediated by ε-polylysine and chlorogenic acid (CGA), as well as inhibition of bacterial protein synthesis induced by BBR. Concurrently, the released CAT and BBR provide ROS scavenging, while CGA contributes antioxidant activities, collectively alleviating oxidative stress, inhibiting macrophage M1 polarization, promoting cell migration, and facilitating angiogenesis. This hierarchical design achieves rapid bactericidal action alongside sustained microenvironment remodeling. Based on these merits, BBR/CAT@Gel rapidly cleared infection and achieved complete epidermal regeneration with well-organized collagen deposition in a mouse model of infected chronic wounds. This work establishes a rationally designed, microenvironment-adaptive hydrogel platform that integrates hierarchical therapeutic mechanisms, offering a compelling strategy for advanced chronic wound management.
- Open Access
- 12 June 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (7) , 102868
Non-genetically reprogrammed meta-neutrophils potentiate chemo-immunotherapy against lung metastatic triple-negative breast cancer
- 12 June 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (7) , 102868
Open AccessNon-genetically reprogrammed meta-neutrophils potentiate chemo-immunotherapy against lung metastatic triple-negative breast cancer
- Open Access
- 30 May 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38, 103297
Sprayable asymmetric hydrogel prevents postoperative pleural adhesions via physical and biological dual therapy
- 30 May 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38, 103297
Open AccessSprayable asymmetric hydrogel prevents postoperative pleural adhesions via physical and biological dual therapy
- 4 April 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 394, 114903
Biomimetic trident lipid anchoring enables stable neutrophil-based combination therapy
- 4 April 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 394, 114903
Biomimetic trident lipid anchoring enables stable neutrophil-based combination therapy
- Open Access
- 17 September 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (1) , 423-443
Dual metabolic-inflammation modulation in MicroRNA@neutrophil-derived microvesicles achieve robust osteoarthritis therapy
- 17 September 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (1) , 423-443
Open AccessDual metabolic-inflammation modulation in MicroRNA@neutrophil-derived microvesicles achieve robust osteoarthritis therapy
- 29 April 2025
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 253, 114745
Injectable laponite nanocomposite hydrogel with synergistic antibacterial and odontogenic activity for endodontic regeneration
- 29 April 2025
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 253, 114745
Injectable laponite nanocomposite hydrogel with synergistic antibacterial and odontogenic activity for endodontic regeneration
- 28 April 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 383, 113779
Sequentially conquering transfection obstacles of primary human T cells via non-classical lipid nanoparticles delivering reformative transposon system
- 28 April 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 383, 113779
Sequentially conquering transfection obstacles of primary human T cells via non-classical lipid nanoparticles delivering reformative transposon system
- Open Access
- 13 May 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-17
Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN
Tyrosine kinase inhibitors have been the standard treatment for patients with Philadelphia chromosome-positive (Ph+) leukemia. However, a series of issues, including drug resistance, relapse and intolerance, are still an unmet medical need. Here, we report the targeted siRNA-based lipid nanoparticles in Ph+ leukemic cell lines for gene therapy of Ph+ leukemia, which specifically targets a recently identified NEDD8 E3 ligase RAPSYN in Ph+ leukemic cells to disrupt the neddylation of oncogenic BCR-ABL. To achieve the specificity for Ph+ leukemia therapy, a single-chain fragment variable region (scFv) of anti-CD79B monoclonal antibody was covalently conjugated on the surface of OA2-siRAPSYN lipid nanoparticles to generate the targeted lipid nanoparticles (scFv-OA2-siRAPSYN). Through effectively silencing RAPSYN gene in leukemic cell lines by the nanoparticles, BCR-ABL was remarkably degraded accompanied by the inhibition of proliferation and the promotion of apoptosis. The specific targeting, therapeutic effects and systemic safety were further evaluated and demonstrated in cell line-derived mouse models. The present study has not only addressed the clinical need of Ph+ leukemia, but also enabled gene therapy against a less druggable target.
- 13 May 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-17
Open AccessTargeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN
Tyrosine kinase inhibitors have been the standard treatment for patients with Philadelphia chromosome-positive (Ph+) leukemia. However, a series of issues, including drug resistance, relapse and intolerance, are still an unmet medical need. Here, we report the targeted siRNA-based lipid nanoparticles in Ph+ leukemic cell lines for gene therapy of Ph+ leukemia, which specifically targets a recently identified NEDD8 E3 ligase RAPSYN in Ph+ leukemic cells to disrupt the neddylation of oncogenic BCR-ABL. To achieve the specificity for Ph+ leukemia therapy, a single-chain fragment variable region (scFv) of anti-CD79B monoclonal antibody was covalently conjugated on the surface of OA2-siRAPSYN lipid nanoparticles to generate the targeted lipid nanoparticles (scFv-OA2-siRAPSYN). Through effectively silencing RAPSYN gene in leukemic cell lines by the nanoparticles, BCR-ABL was remarkably degraded accompanied by the inhibition of proliferation and the promotion of apoptosis. The specific targeting, therapeutic effects and systemic safety were further evaluated and demonstrated in cell line-derived mouse models. The present study has not only addressed the clinical need of Ph+ leukemia, but also enabled gene therapy against a less druggable target.
- Open Access
- 14 November 2022
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 11 (1) , 263-277
Single-component lipid nanoparticles for engineering SOCS1 gene-silenced dendritic cells to boost tumor immunotherapy
Single-component lipid nanoparticles are designed and prepared for delivery of SOCS1 siRNA to primary DCs, which can be further pulsed with Ova-antigen to fabricate a SOCS1-downregulated DC vaccine with the potential to boost antitumor immunotherapy.
- 14 November 2022
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 11 (1) , 263-277
Open AccessSingle-component lipid nanoparticles for engineering SOCS1 gene-silenced dendritic cells to boost tumor immunotherapy
Single-component lipid nanoparticles are designed and prepared for delivery of SOCS1 siRNA to primary DCs, which can be further pulsed with Ova-antigen to fabricate a SOCS1-downregulated DC vaccine with the potential to boost antitumor immunotherapy.
- 1 June 2022
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 187, 114380
An EPR-Independent extravasation Strategy: Deformable leukocytes as vehicles for improved solid tumor therapy
- 1 June 2022
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 187, 114380
An EPR-Independent extravasation Strategy: Deformable leukocytes as vehicles for improved solid tumor therapy